OncoMatch/Clinical Trials/NCT06841172
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Is NCT06841172 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Systemic therapy (Continuation of current first-line systemic therapy) and Systemic therapy (Early switch to second-line systemic therapy) for oligoprogressive metastatic disease.
Treatment: Systemic therapy (Continuation of current first-line systemic therapy) · Systemic therapy (Early switch to second-line systemic therapy) — This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Excluded: AFP elevated (≥10,000 ng/mL at the time of oligoprogression)
Alpha-fetoprotein (AFP) level ≥10,000 ng/mL at the time of oligoprogression
Disease stage
Required: Stage BCLC STAGE C (BCLC)
Metastatic disease required
BCLC stage C at the time of first-line systemic treatment
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy — first-line
Patients must have experienced oligoprogression while receiving their current FLST and must not have previously received any other FLST that resulted in disease progression. The current FLST must have maintained disease stability (SD) for at least three months prior to the occurrence of oligoprogression.
Cannot have received: systemic therapy as adjuvant after curative surgery
Patients who received FLST as adjuvant treatment after curative surgery for HCC
Cannot have received: radiation therapy
Exception: to the site of the oligoprogressive lesion
Previous radiation therapy to the site of the oligoprogressive lesion
Lab requirements
Liver function
child-pugh score ≤7 points
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06841172 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy as adjuvant after curative surgery, radiation therapy disqualifies patients from enrollment.
Are patients with AFP alterations eligible?
No. AFP elevated (≥10,000 ng/mL at the time of oligoprogression) is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE C is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages